NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/30/2026 10:21
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6.17 mln
Float2.64 mln
Earnings Date08/07/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
15
/ 100
Significantly lagging
Debt / Equity
0.01
Debt-free
ROE
-299
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Processa Pharmaceuticals is a Florida-based clinical-stage drug development company focused on improving existing cancer treatments by modifying already-approved drugs to make them safer and more effective. Rather than creating entirely new compounds, the company refines how drugs are processed and distributed by the body while preserving their ability to target cancer cells. Beyond oncology, Processa is also developing treatments for kidney diseases and digestive disorders. Founded in 2015, the company works through licensing partnerships with several pharmaceutical organizations to advance its pipeline.
